摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-iminomorpholin hydrochloride | 623564-41-0

中文名称
——
中文别名
——
英文名称
3-iminomorpholin hydrochloride
英文别名
morpholin-3-ylideneamine hydrochloride;5,6-Dihydro-2H-1,4-oxazin-3-amine hydrochloride;3,6-dihydro-2H-1,4-oxazin-5-amine;hydrochloride
3-iminomorpholin hydrochloride化学式
CAS
623564-41-0
化学式
C4H8N2O*ClH
mdl
——
分子量
136.581
InChiKey
DHDKXNIINMVSNZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    47.6
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    3-iminomorpholin hydrochloride对甲苯磺酸异丙醇sodium methylate三乙胺 作用下, 以 环己烷甲醇乙醇氯仿 为溶剂, 反应 4.0h, 以36.3%的产率得到5,6-二氢-8H-咪唑并[2,1-c][1,4]恶嗪-2-甲醛
    参考文献:
    名称:
    [EN] BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS
    [FR] PENEMES 6-ALKYLIDENE BICYCLIQUES UTILISES EN TANT QU'INHIBITEURS DE ss-LACTAMASES
    摘要:
    本发明提供了一种化合物(I)的配方、药物组合物以及其用于治疗患有细菌感染或疾病的患者的用途。
    公开号:
    WO2003093279A1
  • 作为产物:
    描述:
    5-methylsulfanyl-3,6-dihydro-2H-1,4-oxazine 在 ammonium chloride 作用下, 以 乙醇 为溶剂, 以97.7%的产率得到3-iminomorpholin hydrochloride
    参考文献:
    名称:
    Process for preparing 6-alkylidene penem derivatives
    摘要:
    本发明提供了一种制备式I化合物的方法,该化合物对治疗细菌感染或疾病有用。
    公开号:
    US20040132708A1
点击查看最新优质反应信息

文献信息

  • Process for preparing 6-alkylidene penem derivatives
    申请人:Wyeth
    公开号:US20040132708A1
    公开(公告)日:2004-07-08
    The present invention provides a process of making compounds of formula I, which are useful for the treatment of bacterial infection or disease. 1
    本发明提供了一种制备式I化合物的方法,该化合物对治疗细菌感染或疾病有用。
  • Bicyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors
    申请人:Mansour Suhayl Tarek
    公开号:US20060276445A1
    公开(公告)日:2006-12-07
    This invention relates to certain bicyclic 6-alkylidene penems which act as a inhibitor of class-D enzymes. β-Lactamases hydrolyze β-lactam antibiotics, and as such serve as the primary cause of bacterial resistance. The compounds of the present invention when combined with β-lactam antibiotics will provide an effective treatment against life threatening bacterial infections. In accordance with the present invention there are provided compounds of general formula I or a pharmaceutically acceptable salt or in vivo hydrolyzable ester R 5 thereof: wherein: One of A and B denotes hydrogen and the other an optionally substituted fused bicyclic heteroaryl group; and X═O or S.
    这项发明涉及某些具有双环6-烷基亚烯基青霉素结构的化合物,其作为D类酶的抑制剂。β-内酰胺酶水解β-内酰胺类抗生素,因此是细菌耐药的主要原因。本发明的化合物与β-内酰胺类抗生素结合后,将提供一种有效的治疗方法,用于治疗威胁生命的细菌感染。根据本发明,提供了一般式I的化合物,或其药学上可接受的盐或体内可水解的酯R5:其中:A和B中的一个表示氢,另一个表示可选择取代的融合双环杂环芳基团;X=O或S。
  • BICYCLOAMINE DERIVATIVES
    申请人:Ozaki Fumihiro
    公开号:US20090270369A1
    公开(公告)日:2009-10-29
    Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R 1 , R 2 and R 3 represent hydrogen, etc., X 1 represents C 1-6 alkylene, etc., X 2 represents C 1-6 alkylene, etc., A 1 represents a 5- to 6-membered heterocyclic group, etc., and A 2 represents C 6-14 aryl, etc.
    由式(I)表示的化合物及其药学上可接受的盐具有出色的钠通道抑制作用,并可用作治疗剂和各种神经痛、神经病、癫痫、失眠、早泄等的镇痛剂。其中Q代表乙烯等,R1、R2和R3代表氢等,X1代表C1-6烷基等,X2代表C1-6烷基等,A1代表5-至6-成员杂环基团等,A2代表C6-14芳基等。
  • [EN] PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES<br/>[FR] PROCEDE DE PREPARATION DE DERIVES DE 6-ALKYLIDENE PENEM
    申请人:WYETH CORP
    公开号:WO2003093277A1
    公开(公告)日:2003-11-13
    The present invention provides a process of making compounds of Formula (I), which are useful for the treatment of bacterial infection or disease.
    本发明提供了一种制备化合物的方法,该化合物符合式(I),对于治疗细菌感染或疾病非常有用。
  • Processes For Preparing Bicyclic Oxazine Carboxaldehyde and Beta-Lactamase Inhibitors
    申请人:Kremer Kenneth Alfred Martin
    公开号:US20090018332A1
    公开(公告)日:2009-01-15
    The invention relates to processes for the preparation of the bicyclic oxazine carboxaldehyde Compound 1: The invention also relates to the use of Compound 1 in the preparation of □-lactamase inhibitors.
    本发明涉及制备双环氧噁啉羰基醛化合物1的工艺。本发明还涉及将化合物1用于制备□-内酰胺酶抑制剂的用途。
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 6-amino-4-phenyl-4H-1,2-oxazine-3,5-dicarbonitrile (2S,5R)-2-hydroxy-5,6-dihydro-2-ethyl-3-methyl-5-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-3-methyl-2,5-diphenyl-2H-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3,5-trimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-6-phenyl-2-propyl-2H-1,4-oxazine (Z)-methyl-2-((R)-5-(2-(methylthio)ethyl)-3-oxomorpholin-2-ylidene)acetate (Z)-methyl-2-((R)-5-benzyl-3-oxomorpholin-2-ylidene)acetate (2R,5R,6S)-5,6-dihydro-3,6-diphenyl-2-hydroxy-5-methyl-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine 2-heptafluoropropyl-3-trifluoromethyl-5,6-dihydro-1,4-oxazin-2-ol (2S,5R,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine 6H-1,2-Oxazine 4,4,6-Trimethyl-2-dimethylamino-4H-1,3-oxazine 3-(chloromethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 3-(acetoxymethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 6-Butyl-2,4-diphenyl-4H-[1,3]oxazine 2-methyl-2,4,6-triphenyl-2H-1,3-oxazine (S)-2,4,6-triphenyl-4H-1,3-oxazine 2-Isopropenyl-6-phenyl-6-piperidin-1-yl-6H-[1,3]oxazin-4-ol 5-methyl-6-perhydroxy-3-phenyl-6H-1,2-oxazine 5-methyl-3-phenyl-6-(prop-2-yn-1-oxy)-6H-1,2-oxazine 2,2,3,3,6,6-Hexafluoro-5-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-3,6-dihydro-2H-[1,4]oxazine 4,4-Dimethyl-2-phenyl-1,3-oxazine (R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one Acetic acid 3,5-dimethyl-6-oxo-3,6-dihydro-2H-[1,4]oxazin-3-ylmethyl ester (2R,5R)-3-methyl-5-phenyl-2-(trifluoromethyl)-5,6-dihydro-2H-1,4-oxazin-2-ol